Equillium, Inc.
EQ Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.25
KIRA · Stoqly’s AI analyst, in plain words
- Equillium, Inc. lost $22.4M in fiscal 2025.
- Free cash flow was −$22.8M in fiscal 2025, — of revenue.
Market cap
$140M
P/E
—
Revenue
—
Net income
−$22.4M
Free cash flow
−$22.8M
Operating margin
—
Equillium, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$22.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Equillium, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Equillium, Inc.
- CIK
- 0001746466
Equillium, Inc. · EQ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $15.8M | $36.1M | $41.1M | — |
| Revenue growth | — | — | 129.0% | 13.9% | — |
| Operating margin | — | −393.9% | −40.2% | −20.1% | — |
| Net income | −$39.1M | −$62.4M | −$13.3M | −$8.1M | −$22.4M |
| Net margin | — | −396.1% | −37.0% | −19.6% | — |
| Diluted EPS | −$1.36 | −$1.85 | −$0.38 | −$0.23 | −$0.39 |
| Cash | |||||
| Cash from operations | −$32.1M | −$8.7M | −$21.8M | −$19.0M | −$22.7M |
| Capital expenditure | $0.1M | $0.3M | $0.1M | $0.1M | $0.0M |
| Free cash flow | −$32.1M | −$9.0M | −$21.8M | −$19.1M | −$22.8M |
| FCF margin | — | −57.2% | −60.5% | −46.5% | — |
| Share buybacks | — | — | $0.3M | — | — |
| Share count change | 41.5% | 17.1% | 3.0% | 1.8% | 62.1% |
| Debt and strength | |||||
| Cash and short-term investments | $80.7M | $71.0M | $40.9M | $22.6M | $30.3M |
| Debt incl. finance leases | $10.2M | $9.1M | — | — | — |
| Shareholders' equity | $66.5M | $31.9M | $22.6M | $19.1M | $28.6M |
| Current ratio | 9.4x | 2.4x | 1.8x | 3.9x | 10.6x |
| Interest coverage | −35.2x | −59.0x | −29.6x | — | — |
| Returns and quality | |||||
| Return on equity | −57.3% | −126.8% | −48.9% | −38.8% | −94.0% |
| Return on tangible equity | −58.7% | −195.4% | −59.1% | −42.3% | −78.3% |
| Piotroski F-score | 1 | 2 | 2 | 2 | — |
| Altman Z'' | 2.2 | −8.0 | −10.2 | −19.0 | −12.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.4M
3 insiders
Of sales under plans
70%
$1.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Equillium, Inc. · EQ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.25 a share, the company is worth $140M.
Source: SEC EDGAR XBRL filings (CIK 0001746466). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.